Discussion
Most people with highly active relapsing multiple sclerosis (MS) who received the approved therapy Mavenclad (cladribine) maintained their cognitive function over four years, while experiencing improved quality of life. That’s according to pooled results from 280 patients who completed the global Phase 4 CLARIFY-MS clinical trial (NCT03369665),…